Sign in

    Pfizer Inc (PFE)

    You might also like

    Business Description

    Pfizer Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacture, marketing, sale, and distribution of biopharmaceutical products worldwide . The company operates primarily through its Biopharma segment, which significantly contributes to its total revenues . Pfizer's product offerings include major products like Comirnaty and Paxlovid, alongside other notable products such as Eliquis, the Prevnar family, and the Vyndaqel family .

    1. Biopharma Segment - Focuses on the development and commercialization of biopharmaceutical products, contributing significantly to the company's revenues.
      • Oncology - Includes products like Ibrance, Xtandi, and Inlyta, aimed at treating various types of cancer .
      • Primary Care - Features products such as Eliquis, the Prevnar family, and Paxlovid, addressing common health conditions .
      • Specialty Care - Offers products like Xeljanz and the Vyndaqel family, targeting specific medical needs .
    2. Pfizer Ignite - Engages in business development activities, including acquisitions and collaborations, to enhance the product pipeline and market presence .
    3. PC1 - Involves other business activities that support the company's overall operations .

    Key Metrics

    View all financials →

    Executive Team

    NamePositionStart DateShort Bio
    Albert BourlaChairman of the Board and Chief Executive OfficerJanuary 2019Albert Bourla has been the Chairman of the Board of Pfizer since January 2020 and the Chief Executive Officer since January 2019. He previously served as Chief Operating Officer from January 2018 until December 2018. Bourla has been a director of Pfizer since February 2018 .
    Chris BoshoffChief Oncology Officer, Executive Vice PresidentDecember 2023Chris Boshoff is the Chief Oncology Officer and Executive Vice President at Pfizer. He has been in this role since December 2023. Prior to this, he served as the Chief Oncology Research and Development Officer and Executive Vice President from July 2023 until December 2023 .
    David M. DentonChief Financial Officer, Executive Vice PresidentMay 2022David M. Denton has been serving as the Chief Financial Officer and Executive Vice President of Pfizer since May 2022. Before joining Pfizer, he was the Executive Vice President and Chief Financial Officer at Lowe's Companies, Inc. from November 2018 to April 2022 .
    Alexandre de GermayChief International Commercial Officer, Executive Vice PresidentDecember 2023Alexandre de Germay is the Chief International Commercial Officer and Executive Vice President at Pfizer. He has held this position since December 2023. Prior to this role, he was the Chief Executive Officer at Laboratoires Majorelle, a specialty pharma company in France, from 2021 until January 2024 .
    Mikael DolstenChief Scientific Officer, President, Pfizer Research and DevelopmentJuly 2023Mikael Dolsten, M.D., Ph.D., has been serving as the Chief Scientific Officer and President of Pfizer Research & Development since July 2023. Prior to this role, he was the Chief Scientific Officer and President of Worldwide Research, Development, and Medical from January 2019 until July 2023 .
    Lidia FonsecaChief Digital and Technology Officer, Executive Vice PresidentJanuary 2019Lidia Fonseca has been serving as the Chief Digital and Technology Officer, Executive Vice President at Pfizer since January 2019. Before joining Pfizer, she was the Chief Information Officer and Senior Vice President of Quest Diagnostics Incorporated from 2014 to 2018 .
    Rady A. JohnsonChief Compliance, Quality and Risk Officer, Executive Vice PresidentJanuary 2019Rady A. Johnson has been serving as the Chief Compliance, Quality and Risk Officer, Executive Vice President at Pfizer since January 2019. Prior to this role, he was the Executive Vice President, Chief Compliance and Risk Officer from December 2013 until December 2018 .
    Douglas M. LanklerGeneral Counsel, Executive Vice PresidentDecember 2013Douglas M. Lankler has been serving as General Counsel and Executive Vice President at Pfizer since December 2013. Prior to this role, he was the Executive Vice President and Chief Compliance and Risk Officer from February 2011 until December 2013 .
    Aamir MalikChief U.S. Commercial Officer, Executive Vice PresidentDecember 2023Aamir Malik is the Chief U.S. Commercial Officer and Executive Vice President at Pfizer. He has held this position since December 2023. Prior to this role, he served as the Chief Business Innovation Officer and Executive Vice President from August 2021 until December 2023 .
    Michael McDermottChief Global Supply Officer, Executive Vice PresidentJanuary 2022Michael McDermott has been serving as the Chief Global Supply Officer, Executive Vice President at Pfizer since January 2022. Prior to this role, he was the President of Pfizer Global Supply from 2018 until 2021 .
    Payal SahniChief People Experience Officer, Executive Vice PresidentJanuary 2022Payal Sahni has been serving as the Chief People Experience Officer, Executive Vice President at Pfizer since January 2022. Prior to this role, she was the Chief Human Resources Officer, Executive Vice President from June 2020 to December 2021 .
    Sally SusmanChief Corporate Affairs Officer, Executive Vice PresidentJanuary 2019Sally Susman has been the Chief Corporate Affairs Officer and Executive Vice President at Pfizer since January 2019. Prior to this role, she served as Executive Vice President, Corporate Affairs from December 2010 until December 2018 .

    Questions to Ask Management

    1. Given that operating cash flow is significantly below typical levels this year due to timing of payments and one-time expenses, how does Pfizer plan to maintain and grow its dividend over time while also deleveraging the balance sheet to meet its gross leverage target of 3.25x?

    2. With the expected continued focus on execution to deliver in the second half, considering the seasonality of respiratory products, can you elaborate on the specific risks that might prevent Pfizer from achieving its raised revenue guidance and how you plan to mitigate them?

    3. You mentioned aiming to return to pre-pandemic operating margins on a mix-adjusted basis, excluding COMIRNATY; given that your Manufacturing Optimization Program's $1.5 billion in savings won't be fully realized until 2027, what additional measures are you taking to improve margins in the near term, especially as you head into IRA territory?

    4. Regarding the next-generation Prevnar vaccine, with competitors potentially offering higher serotype coverage, how confident are you in your ability to retain market leadership, and can you provide more specifics on the serotype coverage and timeline for your next-gen PCV candidate?

    5. Considering the importance of ELREXFIO in achieving your oncology strategy goals, and in light of a competitive market, what gives you confidence in the $4 billion opportunity, and can you share any early indicators from the launch that support this target?

    Share Repurchase Program

    Program DetailsProgram 1
    Approval DateN/A
    End Date/DurationN/A
    Total additional amountN/A
    Remaining authorization$3.3 billion
    DetailsPart of Pfizer's capital allocation strategy, focusing on reinvesting in the business, growing dividends, and making value-enhancing share repurchases. Share repurchases are not currently a high priority compared to other strategies.

    Auditor

    NameStart DateEnd DateReason for Change
    KPMG LLPAt least 1942 PresentCurrent auditor

    Latest news

    Recent developments and announcements about PFE.

    Financial Reporting

      Earnings Report

      ·
      Dec 17, 2024, 1:07 PM

      Pfizer's Full-Year 2025 Financial Guidance

      Pfizer has released its full-year 2025 financial guidance, projecting revenues in the range of $61.0 to $64.0 billion. This guidance reflects expectations for operational revenue growth of approximately flat to 5% from the midpoint of the 2024 baseline guidance, which excludes non-recurring items from 2024 .

      The company anticipates full-year 2025 Adjusted Diluted EPS to be between $2.80 and $3.00, representing an operational growth of 10% to 18% from the midpoint of the 2024 baseline guidance .

      Key Financial Trends and Initiatives

      • Cost Savings: Pfizer achieved $4.0 billion in net cost savings through 2024 and expects an additional $500 million in savings in 2025 from its ongoing cost realignment program .
      • Manufacturing Optimization: The first phase of Pfizer's Manufacturing Optimization Program is on track to deliver initial net cost savings in the latter part of 2025, aiming to improve gross margin performance .
      • Impact of Legislation: The 2025 revenue guidance considers an anticipated net unfavorable impact of approximately $1 billion due to changes from the Inflation Reduction Act (IRA) Part D Redesign, which affects Medicare Part D benefit design .

      Overall, Pfizer is focusing on disciplined execution and strategic initiatives to enhance its financial performance and shareholder value in 2025 .

    Legal & Compliance

      Legal Proceedings

      ·
      Dec 17, 2024, 1:07 PM

      Summary of the Legal Matter Involving Pfizer (PFE):

      Key Parties Involved:

      • Pfizer Inc. is the primary party involved in the legal and regulatory matters discussed.

      Nature of the Proceedings:

      • Pfizer is facing various legal and regulatory challenges, including those related to government regulations, healthcare reforms, and legal proceedings. These include potential impacts from U.S. healthcare reforms, pharmaceutical product pricing regulations, and intellectual property issues .
      • The company is also dealing with legal defense costs, insurance expenses, settlement costs, and contingencies related to legal proceedings and environmental contamination .
      • There are risks associated with tax-related litigation and investigations, as well as potential adverse decisions or settlements in ongoing legal proceedings .

      Potential Financial or Operational Consequences:

      • Pfizer anticipates a negative revenue impact of approximately $1 billion in 2025 due to changes in the Medicare Part D benefit design under the Inflation Reduction Act, which will affect their revenue streams .
      • The company has achieved $4 billion in net cost savings through 2024 and expects an additional $500 million in savings in 2025 from ongoing cost realignment programs .
      • Pfizer's financial guidance for 2025 includes expected revenues of $61.0 to $64.0 billion and adjusted diluted EPS of $2.80 to $3.00, reflecting operational growth and cost management efforts .

      Overall, Pfizer is navigating a complex landscape of legal and regulatory challenges that could have significant financial and operational impacts. The company is actively managing these risks through strategic cost-saving initiatives and careful financial planning .